Kurma Partners

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Ganymed Robotics SAS, established in 2018 and headquartered in Paris, France, specializes in the development of advanced robotics technologies tailored for orthopedic surgeons. The company's primary focus is on creating a therapeutic device designed to enhance surgical precision during knee replacement procedures. This innovative technology aims to improve patient outcomes, surgeon experience, and overall efficiency of care delivery by leveraging robotic assistance to reduce operating time.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a significant discovery that identifies CXCR4 as a master regulator of inflammation. This breakthrough positions Ermium Therapeutics to create therapies that control interferons through plasmacytoid dendritic cells, offering potential new treatment options for patients suffering from these conditions. The company has secured a worldwide exclusive license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which supported the project's academic maturation. Ermium Therapeutics has also been recognized for its innovative approach, winning the i-Lab 2019 award from the French Ministry of Research and Higher Education.

DAMAE Medical, established in 2014 and headquartered in Paris, France, specializes in developing innovative medical devices for dermatological applications. The company's flagship product, OCTAV, employs advanced optical imaging technology to provide dermatologists with high-resolution, in-depth images of skin tissue, similar to traditional histology, but without the need for tissue excision or processing. This non-invasive, in-vivo imaging modality enables precise, efficient, and rapid evaluation of skin tumors, aiding in the diagnosis of skin cancers. DAMAE Medical's mission is to harness the power of bio-photonics to revolutionize medical imaging and diagnosis in dermatology.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

MedLumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company develops integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method that offers detailed sectional information about tissue. MedLumics' radiofrequency cardiac ablation system provides real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation enhances procedural safety, reduces technical complexity, and lowers recurrence rates for patients undergoing treatment.

Corlieve Therapeutics SAS is a biotechnology company based in Paris, France, dedicated to developing innovative therapeutic options for patients suffering from severe neurological disorders. Founded in 2019, the company focuses on a lead project that targets aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) through a gene therapy approach. This novel AAV gene therapy program aims to address refractory TLE, leveraging scientific research from notable institutions such as INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. By advancing its therapeutic strategies, Corlieve Therapeutics seeks to enhance the quality of life for individuals impacted by these challenging conditions.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Ermium Therapeutics is a biotechnology company based in Paris, France, focused on developing innovative therapies for autoimmune and inflammatory diseases. Founded in June 2019, the company is centered around a significant discovery that identifies CXCR4 as a master regulator of inflammation. This breakthrough positions Ermium Therapeutics to create therapies that control interferons through plasmacytoid dendritic cells, offering potential new treatment options for patients suffering from these conditions. The company has secured a worldwide exclusive license for its intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which supported the project's academic maturation. Ermium Therapeutics has also been recognized for its innovative approach, winning the i-Lab 2019 award from the French Ministry of Research and Higher Education.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

DAMAE Medical, established in 2014 and headquartered in Paris, France, specializes in developing innovative medical devices for dermatological applications. The company's flagship product, OCTAV, employs advanced optical imaging technology to provide dermatologists with high-resolution, in-depth images of skin tissue, similar to traditional histology, but without the need for tissue excision or processing. This non-invasive, in-vivo imaging modality enables precise, efficient, and rapid evaluation of skin tumors, aiding in the diagnosis of skin cancers. DAMAE Medical's mission is to harness the power of bio-photonics to revolutionize medical imaging and diagnosis in dermatology.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development, manufacture, and marketing of innovative patient monitoring systems. The company's primary focus is on delivering critical indicators related to tissue perfusion, which are essential for clinicians in assessing patient health. The recent launch of the IKORUS® monitoring system addresses a significant gap in patient monitoring by facilitating the early detection of microcirculatory alterations. This system not only enhances clinical assessment of intestinal tissue perfusion but also guides novel circulatory therapies and informs new approaches to resuscitation. By providing these tools, Advanced Perfusion Diagnostics aims to reduce patient complications and overall treatment costs, ultimately improving therapeutic practices and patient outcomes.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development, manufacture, and marketing of innovative patient monitoring systems. The company's primary focus is on delivering critical indicators related to tissue perfusion, which are essential for clinicians in assessing patient health. The recent launch of the IKORUS® monitoring system addresses a significant gap in patient monitoring by facilitating the early detection of microcirculatory alterations. This system not only enhances clinical assessment of intestinal tissue perfusion but also guides novel circulatory therapies and informs new approaches to resuscitation. By providing these tools, Advanced Perfusion Diagnostics aims to reduce patient complications and overall treatment costs, ultimately improving therapeutic practices and patient outcomes.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.